Last week saw the launch of the government’s long-awaited National Cancer Plan for England, built around one simple promise: by 2035, three-quarters of people diagnosed with cancer will be cancer-free or living well five years on. If achieved, ministers estimate this could mean 320,000 additional lives saved cumulatively by 2035. It sits alongside the broader NHS 10-Year Health Plan and is one of the few disease-specific strategies published in this parliament, signalling cancer as an early test of delivery.
It is a bold statement of intent. The real test now is whether the NHS can turn that ambition into consistent delivery across England.
At its core, the Plan puts patients back at the centre of the pathway. There is a clear shift towards more personalised care, with every patient promised a tailored cancer plan and ongoing support from a named clinical lead. Digital tools, including the NHS App and a Single Patient Record, are intended to make it easier to manage appointments, access information and coordinate care.
Much of the strategy hinges on earlier diagnosis. Targets to increase stage 1–2 detection, reduce emergency presentations and expand screening programmes are backed by investment in diagnostics and continued rollout of Community Diagnostic Centres. Genomics, biomarker testing and liquid biopsies are positioned as routine parts of care rather than specialist add-ons. If these measures shorten the time from suspicion to treatment, the impact on outcomes could be significant.
There is also a strong focus on reducing service variation. The Plan looked at regional variations and ICB-level performance data, highlighting stark differences in how quickly patients are diagnosed, treated, with some systems weeks or months faster than others. Equalising performance between Integrated Care Boards – bringing the slowest closer to the fastest – in reality, may make more difference to patients than any wholesale reforms.
But this is where the tension lies. Key metrics had not been met prior publication of the Plan: the 62-day treatment target has not been achieved nationally since 2014, and the Faster Diagnosis Standard continues to fluctuate below its ambition. At the same time, the NHS is undergoing major organisational change, as part of Labour’s wider mission to rebuild performance and cut waiting times across the service. ICBs are expected to take on greater delivery responsibilities while managing restructuring, implementing 50% cuts to running and transformation budgets, and the abolition of NHSE. Crucially, many of the Plan’s commitments come without new funding attached, which questions the feasibility of implementation.
For industry, the picture is similarly mixed. Faster trials, genomics and adoption pathways are positive signals, but questions remain in implementation. Progress has been made on commitments to medicine spend as a percentage of GDP and to medicines pricing thresholds and rebate rates – but there are few wholesale reforms to reimbursement or access mechanisms. Additionally, indication-specific pricing remains unaddressed. As explored from a system perspective, structural barriers to uptake remain largely unchanged.
Overall, the Plan sets a clear direction: earlier diagnosis, more personalised care and less variation. The ambition is credible. The challenge will be translating national commitments into consistent delivery across a stretched and restructuring system.
Whether three in four becomes reality will depend less on policy and more on system capacity, leadership and funding. For industry, the route to impact is through shaping how the Plan is implemented in practice – working with government and systems locally to demonstrate value and support delivery.
To discuss these insights and what they could mean for you and your organisation, please get in touch with Daisy Thomas, Managing Partner for Healthcare and Life Sciences, at [email protected].
Portland brings together expertise from across healthcare and life sciences, international development and technology. We enable clients to be bigger and bolder, engage priority audiences, and run campaigns that lift health and wellbeing around the world. Grounded in a clear view of the global health system and powered by in-house research, our strategies align with rapidly changing policy across every level.
